Metronidazole Noridem (Metronidazole)

Metronidazole is taken up by susceptible microorganisms and reduced by anaerobic electron‑transport proteins to generate reactive nitro radicals. These radicals bind to DNA, causing strand breakage and inhibiting nucleic acid synthesis, which ultimately leads to bacterial and protozoal cell death.

The specific dose and infusion rate of Metronidazole Noridem are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. No standardized dosing information is provided here.

Metronidazole is classified as pregnancy category unknown in many jurisdictions. Use during pregnancy or lactation should be considered only when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The most common alternative to metronidazole is tinidazole, another nitroimidazole. Both have similar spectra against anaerobic bacteria and protozoa, but tinidazole often has a longer half‑life, allowing less frequent dosing. Choice between them depends on local resistance patterns, patient tolerance, and clinician preference.

Metronidazole Noridem should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture, and extreme temperature fluctuations. Do not freeze the product, and ensure the vial is kept sealed until use.

Metronidazole Noridem is administered intravenously. The solution is typically infused over a prescribed period using a sterile infusion set. Administration should be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and the prescriber's instructions.

Serious adverse events include seizures, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, neutropenia, hepatic toxicity, and peripheral neuropathy. Patients should be monitored for neurological symptoms, skin reactions, liver function changes, and any signs of hypersensitivity, and treatment should be stopped if serious reactions occur.

Metronidazole Noridem is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazoles. Caution is also advised for patients with severe hepatic or renal impairment, and it should be avoided in those with a history of severe neurologic reactions to the drug.